Biotechnology
Filter News
Found 46,686 articles
-
Atreca Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
8/11/2021
Atreca, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, announced financial results for the second quarter ended June 30, 2021, and provided an overview of recent developments.
-
Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update
8/11/2021
Immunocore Holdings plc, a late-stage biotechnology company pioneering the development of a novel class of T cell receptor bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, announced its financial results for the quarter and six months ended June 30, 2021 and provides a portfolio update.
-
Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration
8/11/2021
Surrozen, Inc., a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, announced the completion of its business combination with Consonance-HFW Acquisition Corp., a special purpose acquisition company sponsored by entities affiliated with Consonance Capital Management.
-
Inozyme Pharma Reports Q2 2021 Financial Results and Provides Business Highlights
8/11/2021
Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, reported financial results for the second quarter ended June 30, 2021, and provided recent business highlights.
-
Berkeley Lights and Bayer announce a multi-year agreement aimed at revolutionizing the discovery of next-generation traits
8/11/2021
Berkeley Lights, Inc. a leader in the functional characterization of live biology, announced a multi-year agreement with Bayer to develop and perform high-throughput functional screening workflows aimed at accelerating and expanding the discovery of novel traits.
-
Merz and Israeli Start-Up Vensica Launch Partnership for Needleless Treatment of Overactive Bladder
8/11/2021
wMerz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, and the Israeli start-up Vensica Therapeutics Ltd., a urology company, announced that they have entered into a strategic license and collaboration agreement for the delivery of botulinum neurotoxin A ) to the bladder wall by using Vensica’s innovative ultrasound-assisted delivery catheter.
-
Avacta Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase I Clinical Trial
8/11/2021
Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the first patient has been dosed in its Phase I multicentre trial evaluating AVA6000, a novel pro-drug of Doxorubicin.
-
Immunetune Strengthens Team by Appointing Sijme Zeilemaker as Chief Executive Officer
8/11/2021
Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, announced the appointment of Sijme Zeilemaker as Chief Executive Officer.
-
Vensica Therapeutics Inks Strategic Partnership with Merz
8/11/2021
Vensica Therapeutics, a clinical stage biopharmaceutical company, announced that it has signed a strategic collaboration agreement with Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins Vensica has licensed Merz's botulinum neurotoxin A for needle-free use in urological procedures.
-
GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation
8/11/2021
GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells therapies for immunology, announced it has closed on a Series A financing generating immediate proceeds of $157 million, led by Matrix Capital Management with participation by Avidity Partners, JDRF T1D Fund, seed investors OrbiMed, RA Capital Management, and Novartis Venture Fund, and Seattle Children's Research Institute.
-
Defence Therapeutics Receives DTC Eligibility
8/11/2021
Defence's common shares are now eligible for book entry and depository services of the Depository Trust Company (DTC), which facilitate electronic clearing and settlement of its common shares in the United States.
-
Annovis Bio Completes Dosing of Parkinson's Disease Patients with ANVS401 in Phase 2a Clinical Trial
8/11/2021
The original 14 AD and 14 PD patients were treated with either placebo or 80 mg of ANVS401 once daily.
-
PYC Therapeutics to Host Quarterly Investor Call on August 17 at 9 a.m. AWST | 11 a.m. AEST
8/11/2021
PYC Therapeutics today announced it will host an investor call on August 17, 2021 at 9 a.m. AWST/11 a.m.
-
Virios Therapeutics to Present at the SNN Network Summer Virtual Conference
8/11/2021
Virios Therapeutics, Inc. announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the SNN Network Summer Virtual Conference on August 19, 2021 at 9:00 a.m. ET.
-
In India, only 8.3% of the population is fully vaccinated, while Sudan, Myanmar, and Ethiopia all have blank spaces beside their names in that category.
-
On Monday, BioNTech announced revenues of €5.308 billion (about $6.2 billion) for the quarter.
-
BioLife will obtain all of the outstanding shares of Sexton that it doesn’t already own for $24 million in consideration for 506,382 newly issued shares of BioLife common stock.
-
Indapta Therapeutics Announces New Preclinical Data Demonstrating Proprietary G-NK Cells Enhance Efficacy of Monoclonal Antibodies in Multiple Myeloma
8/10/2021
Indapta Therapeutics , Inc. today announced the publication of new preclinical data in Blood Advances demonstrating Indapta’s proprietary allogeneic FcεRIγ-deficient G-NK cells in combination with an FDA-approved monoclonal antibody (mAb)
-
Moderna and Canada Announce Collaboration to Bring mRNA Manufacturing to Canada
8/10/2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a Memorandum of Understanding (MoU) with the government of Canada to build a state-of-the-art messenger RNA (mRNA) vaccine manufacturing facility in Canada including access to Moderna’s mRNA development engine.
-
MoonLake Immunotherapeutics appoints former Kymab CEO Simon Sturge as Chairman and Spike Loy to the Board of Directors
8/10/2021
MoonLake Immunotherapeutics AG today announced the appointment of Mr. Sturge as Chairman.